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Rapid-acting insulin analogs are increasingly used during type 1 diabetic pregnancy. They may assist women to safely optimize glucose control (1,2), but little is known about their pharmacokinetics and reproducibility in pregnancy. Using a unique data set of 1,300 plasma insulin samples collected under strictly observed experimental conditions, we explored the relationship between aspart pharmacokinetics and clinical and demographic factors. We also assessed reproducibility both within and between pregnant women using continuous subcutaneous insulin infusion (CSII).
In study 1 (ISRCTN62568875), 10 women were studied on two occasions under sedentary conditions with prandial boluses administered before standardized evening and breakfast meals in early (12-16 weeks) and in late (28-32 weeks) gestation (3). In study 2 (ISRCTN50385583), 12 women were studied on two occasions in midgestation (19 and 23 weeks) (4). The boluses were administered before standardized evening and breakfast meals (60-g carbohydrate dinner, 50-g carbohydrate breakfast). Physical activity was encouraged with postprandial walking (20 min after each meal) with 50 min of brisk treadmill walking (3.9 km/h) after breakfast (4). Ethics approval was obtained from Suffolk, Norfolk, and Cambridgeshire (study 1) and Essex 2 Research ethics committees (study 2).
Participants (n 5 22) had a mean age of 32 (4.5) years; diabetes duration, 18 (8.7) years; gestational age, 22 (6.5) weeks; BMI, 27.0 (3.3) kg/m 2 ; and booking HbA 1c , 7.1% (1.0) (54 [10.9] mmol/mol). Each mealtime was considered separately so that the basic unit of study is a time series (5-h profile) of insulin concentration after breakfast or dinner, with 88 profiles from 22 women (40, study 1; 48, study 2).
Plasma insulin concentration (n 5 1,302 measurements) was measured by an immunochemiluminometric assay (Invitron, Monmouth, U.K.) with intraassay coefficient of variation (CV) 4.7% and interassay CV 7.2%-8.1%. A twocompartment model estimated timeto-peak plasma insulin concentration (t max [min]), metabolic clearance rate of insulin (MCR [mL/kg/min]), rate of plasma insulin accumulation (I a [pmol/L/min]), and postprandial plasma insulin concen-
The mean time-to-peak postprandial aspart concentration was 55 min, which was reduced to 40 min after study 2 breakfast (Table 1 ). This suggests that moderate intensity physical activity may speed up prandial insulin absorption. There was strong evidence of delayed aspart absorption with advancing pregnancy. The time-to-peak aspart concentration was delayed by 1.6% per week, meaning that absorption is approximately 50% slower at 38 weeks compared with 8 weeks of gestation. Interestingly, the time-to-peak was faster (1.1% per year) in women with longer duration of type 1 diabetes.
The between-patient variability was less than expected from our comparable data set outside pregnancy (CV for t max 12% and MCR 14%), compared with 33% and 44%, respectively, outside pregnancy (5). During pregnancy, the within-patient variability was striking (CV for t max 29% and MCR 29% and 23%). The percentage of inter-occasion variation out of total variation is high (t max 83% and MCR 71%), implying most variability is occasion-specific rather than individual-specific. This suggests that aspart pharmacokinetics is considerably less reproducible in pregnancy.
In summary, our observations highlight the day-to-day challenges of optimal prandial dosing in type 1 diabetic pregnancy. They suggest that earlier premeal boluses are required as pregnancy advances and that physical activity is a potentially modifiable means for speeding up insulin absorption in pregnancy. to the research staff at the Wellcome Trust clinical research centre (Addenbrooke's Hospital, Cambridge, U.K.) for their excellent clinical care, Dr. Paul Luzio and colleagues (University of Cardiff, Wales, U.K.) for plasma insulin measurements, and to all the study participants for their generous and enthusiastic support. Significant associations are indicated in boldface type. *Estimated probability of association. Only the clinical/demographic factors for which the probability of an association $0.5 are shown. §Accuracy is measured by posterior standard deviation (the Bayesian analog of a standard error). **For t max and MCR, the estimated expected percentage change is shown; for I a and I b , the estimated expected absolute change is shown.
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